Triple Negative Breast Cancer
Who we are
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
